The Use of External-beam Radiotherapy for Muscle-invasive Bladder Cancer in Elderly or Medically-fragile Patients
| Autor: | Masanori Kono, Masato Noguchi, Kazuto Komatsu, Kenji Tsukahara, Tadashi Sagoh, Masakazu Ogura, M. Sakamoto, Rihito Aizawa, Yoshiharu Negoro, Nobuaki Orito |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
0301 basic medicine medicine.medical_specialty Time Factors Frail Elderly medicine.medical_treatment Urinary Bladder Urology Medically fragile Kaplan-Meier Estimate Risk Assessment Disease-Free Survival 03 medical and health sciences 0302 clinical medicine Risk Factors Overall survival Humans Medicine Neoplasm Invasiveness External beam radiotherapy Geriatric Assessment Aged Neoplasm Staging Retrospective Studies Aged 80 and over Bladder cancer Radiotherapy Performance status business.industry Age Factors Muscle invasive Muscle Smooth medicine.disease Radiation therapy Treatment Outcome 030104 developmental biology Urinary Bladder Neoplasms 030220 oncology & carcinogenesis Disease Progression Feasibility Studies Female Dose Fractionation Radiation business |
| Zdroj: | Anticancer Research. 37 |
| Popis: | Aim To evaluate the clinical results of external-beam radiotherapy (EBRT) for muscle-invasive bladder cancer (MIBC) in elderly or medically-fragile patients. Patients and methods Twenty-five consecutive patients with MIBC (cT2-4N0-1M0) receiving EBRT were retrospectively analyzed. Their median age was 82 years. Radiotherapy median dose was 60 Gy administered in 30 fractions. Results Median follow-up period was 14.7 months. Median overall survival (OS) and progression-free survival (PFS) were 14.7 months and 7.8 months, respectively. The OS, cause-specific survival (CSS), and PFS rates at 1-year were 56.0%, 68.5%, and 40.0%, respectively. The local progression-free rates (LPFR) at 6 months and 1 year were 89.3% and 59.5%, respectively. Performance status 3 was a significantly unfavorable factor for OS, CSS, and progression-free survival; clinical N stage was a significantly unfavorable factor for progression-free survival; and lower irradiation dose (≤50.4 Gy) was a significantly unfavorable factor for LPFR. Conclusion EBRT for elderly or medically-fragile patients is feasible, and achieves acceptable local progression-free status. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|